Bacillus clausii SC-109 and Complete Irritable Bowel Syndrome Symptom Relief

• Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.

  • 2022-11-16
  • RCT · n = 130
  • Paediatric drugs 25(1)
  • • Rodrigo Vázquez-Frias
    • Alejandra Consuelo-Sánchez
    • Carlos Patricio Acosta-Rodríguez-Bueno
    • Andrés Blanco-Montero
    • Daniel Casas Robles
    • Vanessa Cohen
    • Daniel Márquez
    • Marcos Perez

  • PubMed: 36380186
  • DOI: 10.1007/s40272-022-00536-9

  4 Insights on

  • Complete Irritable Bowel Syndrome Symptom Relief

  • High evidence
  • Large Human Trial

  For Week 8 SGARC, 19.2% (B. clausii) and 20.9% (placebo) reported complete symptom relief.

  Effect

  Neutral

  Effect size

  Small

  Significant

  No